首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL8 |
| Uniprot No | P80075 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-99aa |
| 氨基酸序列 | QPDSVSIPITCCFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTKRGKE VCADPKERWVRDSMKHLDQIFQNLKP |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL8重组蛋白的假设性参考文献示例(仅供格式参考，具体内容需核实)：
1. **标题**：Expression and Functional Characterization of Recombinant CCL8 in Mammalian Cells
**作者**：Smith A, et al.
**摘要**：报道了在HEK293细胞中重组表达CCL8的优化方法，验证其趋化单核细胞和T细胞的能力，并证明其通过CCR1/CCR5受体介导信号通路。
2. **标题**：CCL8 Promotes Viral Inhibition through Macrophage Recruitment in Murine Models
**作者**：Zhang L, et al.
**摘要**：利用重组CCL8蛋白研究其在流感病毒感染中的作用，发现其通过招募巨噬细胞增强抗病毒反应，降低肺部病毒载量。
3. **标题**：Structural Analysis of Recombinant CCL8 and Its Role in Tumor Microenvironment
**作者**：Brown K, et al.
**摘要**：通过核磁共振解析重组CCL8的三维结构，并证明其通过调控肿瘤相关巨噬细胞极化抑制黑色素瘤生长。
4. **标题**：CCL8 as a Biomarker in Autoimmune Diseases: Recombinant Protein-based Detection
**作者**：Wang X, et al.
**摘要**：开发基于重组CCL8的ELISA检测方法，发现其在类风湿性关节炎患者血清中显著升高，与疾病活动度相关。
---
注：以上文献为示例，实际引用需根据具体研究通过数据库(如PubMed)检索核实。
CCL8 (C-C motif chemokine ligand 8), also known as monocyte chemoattractant protein-2 (MCP-2), is a small secretory protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting leukocytes, including monocytes, lymphocytes, eosinophils, and basophils, to sites of inflammation or infection. CCL8 is produced by various cell types, such as monocytes, fibroblasts, and endothelial cells, in response to pro-inflammatory stimuli like TNF-α, IL-1β, or viral components. Its activity is mediated through binding to chemokine receptors, primarily CCR1. CCR2. CCR3. and CCR5. which are expressed on target immune cells.
Recombinant CCL8 protein is engineered using biotechnology platforms (e.g., E. coli or mammalian expression systems) to ensure high purity and bioactivity. It typically retains the conserved structure of natural CCL8. including a signal peptide and a mature protein domain with characteristic disulfide bonds critical for receptor interaction. Researchers utilize recombinant CCL8 to study chemokine-mediated immune responses, inflammatory diseases (e.g., rheumatoid arthritis, asthma), cancer progression (via tumor microenvironment modulation), and viral infections (e.g., HIV, as CCR5 is a co-receptor). It is also employed in in vitro assays to evaluate cell migration, receptor signaling pathways, and potential therapeutic inhibitors. Quality-controlled batches are validated using techniques like HPLC, SDS-PAGE, and functional cell-based migration assays to ensure consistency for experimental reproducibility.
×
